SCHEMBL2906890

SCHEMBL2906890

COc1cccc(C(=O)Nc2ccc(-c3cc(C(=O)O)ccc3C)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.65
KMT2A Q03164 6/20 0.65
MEN1 O00255 5/20 0.65
NPC1 O15118 4/20 0.64
RAB9A P51151 4/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
TP53 P04637 3/20 0.64
KDM4E B2RXH2 1/20 0.64
TSHR P16473 1/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
ALDH1A1 P00352 1/20 0.62
PKM P14618 1/20 0.62
HPGD P15428 1/20 0.62
MAPK1 P28482 1/20 0.62
HSP90AA1 P07900 1/20 0.59
HSP90AB1 P08238 1/20 0.59
KCNK3 O14649 1/20 0.57
KCNK9 Q9NPC2 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7824945 0.85 KMT2A (0.82) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL13423757 0.85 MAPK14 (0.71) MAPK14KMT2AMEN1NPC1RAB9A
SCHEMBL2914737 0.84 PKM (0.61) MAPK14KMT2AMEN1NPC1RAB9A
SCHEMBL2907501 0.84 SMN1; SMN2 (0.55) MAPK14KMT2AMEN1NPC1RAB9A
SCHEMBL2349159 0.83 MAPT (0.66) MAPK14KMT2AMEN1NPC1RAB9A
SCHEMBL2907086 0.82 HSP90AA1 (0.65) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL23070447 0.80 RAB9A (0.81) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2744367 0.80 MAPT (0.54) MAPK14NPC1RAB9AKDM4EALDH1A1
SCHEMBL12322880 0.79 MAPK14 (0.69) MAPK14KMT2AMEN1NPC1RAB9A
SCHEMBL5345650 0.79 KMT2A (1.00) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 MAPK14 4315/4885KMT2A 3804/4885MEN1 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.